For example, the CoronaVac, Covishield, BBIBP-CorV and Covaxin vaccines are not part of Australia's national vacciation program, however, they are recognised for the purpose of travel to Australia. They may not be approved for the general population. Note that in some countries, vaccines may be authorized solely for travel purposes. Specific versions of another four vaccines are under evaluation by the EMA: Sputnik V, CoronaVac, Sanofi–GSK and Valneva. Specific versions of five vaccines have been authorised by the European Medicines Agency (EMA): Pfizer–BioNTech, Janssen, Novavax, Moderna and Oxford–AstraZeneca. Five others are under assessment by the WHO: Sputnik V, Sinopharm WIBP, Convidecia, Sanofi–GSK and SCB-2019. National regulatory authorities have granted emergency use authorizations for thirty COVID-19 vaccines.Įight vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin and Novavax. For COVID-19 vaccination policy by country, see Vaccination policy § Table.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |